Expired activity
Please go to the PowerPak homepage and select a course.

Current and Emerging Therapies for Non-Cystic Fibrosis Nontuberculous Mycobacterial Lung Disease: What Pharmacists Need to Know

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Insmed Incorporated.


Therapy Name Change: In the presentation, generic inhaled liposomal amikacin is referred to as liposomal amikacin for inhalation (LAI). The correct name of the therapy is amikacin liposome inhalation suspension (ALIS).

Christina G. Rivera, PharmD, BCPS
Instructor of Pharmacy
College of Medicine & Science
Mayo Clinic
Rochester, MN

John D. Zeuli, PharmD, BCPS-AQ ID
Infectious Diseases Clinical Pharmacist
Department of Pharmacy
Mayo Clinic
Rochester, MN


Drs. Zeuli and Rivera have no relevant affiliations or financial relationships with a commercial interest to disclose.

The clinical reviewer, Matthew Casciano, PharmD, BCPS, has no actual or potential conflict of interest in relation to this program.

Susanne Batesko, RN, BSN, Robin Soboti, R.Ph, and Susan R. Grady, MSN-RN-BC, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.


Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-18-021-H01-P
Credits: 1.5 hour (0.15 ceu)

Type of Activity: Application
Media: Internet

Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 90 minutes


August 15, 2018


August 15, 2019


This accredited activity has been designed for pharmacists.


During the period August 15, 2018 through August 15, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the post-test and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


To inform and educate health-system, managed care and specialty pharmacists on the most up-to-date science, treatment options and drug-therapy management for patients with non-cystic fibrosis (non-CF) nontuberculous mycobacterial (NTM) lung disease to optimize patient care and outcomes.


Upon completion of this program, participants should be better able to:

  1. Describe current guideline recommendations for the treatment of patients with non-CF NTM lung disease
  2. Identify common barriers to successful treatment of non-CF NTM lung disease
  3. Formulate effective strategies to overcome common barriers to successful treatment of non-CF NTM lung disease
  4. Recommend appropriate treatment options, including new and emerging therapies, for patients with refractory non-CF NTM lung disease
  5. Formulate effective strategies for monitoring drug therapy, managing adverse effects,  and addressing drug interactions with regimens used to treat non-CF NTM lung disease


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC or Insmed Incorporated. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.